DNAprint Genomics (DNAG)

[Gold Eagle]

NEWS

DNAPrint genomics and ReliaGene Enter Into Agreement

SARASOTA, Fla., Jul 13, 2004 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint genomics (DNAP) of Sarasota, FL (the "Company") announces today that it has entered into a distributorship agreement with ReliaGene Technologies Inc. The agreement enables ReliaGene to distribute DNAPrint's flagship product, DNAWitness(TM) 2.5, to its extensive international client base of law enforcement agencies.

The agreement is expected to significantly expand DNAPrint's footprint in the forensics industry by providing access to a host of additional criminal investigation cases. Any case where no suspect has been identified will be eligible for DNAWitness(TM) 2.5, a ground-breaking genetic test which represents the first-ever DNA-based tool for the inference of physical characteristics from evidence samples. Through a molecular genetic appreciation of genetic ancestry, DNAWitness(TM) 2.5 provides physical information about suspects, victims and unidentified human remains, thereby furnishing invaluable assistance and direction to investigations. ReliaGene is a leading DNA laboratory and research facility with accreditation from the American Society of Crime Lab Directors (ASCLD), National Forensic Science Technology Center (NFSTC), Clinical Laboratory Improvement Amendments (CLIA), American Association of Blood Banks (AABB), and ISO/IEC 17025. ReliaGene regularly serves law enforcement agencies across the country and around the world, and has successfully analyzed over 400,000 biological samples.

"DNAWitness(TM) is a presumptive test that will enable investigators, prosecutors, medical examiners, forensic scientists and crime laboratories all over the world establish a 'fuzzy photograph' of the DNA donor," said Richard Gabriel, CEO and President of DNAPrint genomics, Inc. "The single largest stumbling block to usage of this product on a much broader basis by the forensic community has been the lack of understanding as to how the product works within the current system of evidence control. We now have made arrangements with ReliaGene that ensures that our presumptive test can be used effectively in the early stages of the investigation in addition to when the trail grows cold over time. ReliaGene's role is to control the evidence samples according to ASCLD standards, which it currently does for all its forensic clients, and perform standard DNA profiling when necessary. Select samples will be sent to DNAPrint, which will report the DNAWitness(TM) results back, and the outcome of our combined efforts will be a reduction in unsolved cases as well as the reactivation of many cold cases." He added, "We estimate that about 30% of criminal cases have no suspect (including CODIS suspectless cases) and all of the unidentified human remains stored in crime labs and medical examiner offices across the country are also excellent candidates for DNAWitness."

Dr. Sudhir Sinha, President of ReliaGene, stated, "We are very pleased and excited to have this unique opportunity to work with DNAPrint and accelerate the use of DNAWitness(TM) in the forensics market. ReliaGene has always prided itself on providing the utmost in cutting-edge forensic DNA capabilities. Now, through this partnership, we can offer unprecedented access to this revolutionary investigative tool, which has already assisted in the Louisiana Serial Killer Case, the Concord California Case, the Susannah Chase investigation and a number of other high-profile cases. There is no question that DNAWitness(TM) can greatly benefit our numerous customers in the forensic community. It will help them focus investigations in the crucial early stages, producing substantial time and cost-savings, and can assist in identification of human remains. It also bridges the gap for the countless no-suspect cases without a match on the national DNA database -- cases that might otherwise be shelved as dead-ends. We will focus our efforts on encouraging existing clients to take advantage of DNAWitness(TM), and we intend to secure future contracts by emphasizing this enhanced capability. DNAPrint is capable of processing over 500 samples per day using DNAWitness(TM), and there is no reason not to fully utilize this capability through this partnership," he concluded.

"There are over 70,000 DNA profiles from cases that are unsolved in the national U.S. DNA database. Almost all of them are good candidates for DNAWitness," said Zach Gaskin, Technical Director of Forensics at DNAPrint. "The DNA for those cases is sitting in freezers in crime labs across the country. We should get a portion of those as well as samples from future cases through this agreement with ReliaGene. We are working with ReliaGene to host seminars on the use of DNAWitness(TM) in the investigation process as well as workshops on how to write grants for federal funds available to local and state agencies for crime investigation," said Gaskin. "I would like to see more investigators using DNAWitness(TM) proactively in the early stages of an investigation when the trail is still hot, rather than waiting for the possibility that the person who left the DNA at the crime scene is one of the 1.6 million individuals in the national database known as CODIS. Most government crime labs have serious case backlogs, which do not allow them the luxury of processing cases without a suspect in custody. Many of these no- suspect cases are being sent to ReliaGene, and it seems to be a natural bundle with DNAWitness(TM)."

About ReliaGene Technologies, Inc.

Founded in 1990 and based in the New Orleans, LA metro area, ReliaGene Technologies Inc. is a leading DNA laboratory facility specializing in human genetic identification and related bio-tech product development. With cutting-edge capabilities for forensic and paternity DNA testing, ReliaGene has now successfully detected human genetic profiles from over 400,000 biological samples, including cases from all 50 U.S. states and over 35 countries worldwide. ReliaGene's Y-PLEX(TM) genotyping systems, first released in 2000, are now sold in over 40 countries with market demand increasing steadily. For more information, please visit: http://www.reliagene.com .

About DNAPrint genomics, Inc.

DNAPrint genomics Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company introduced ANCESTRYbyDNA(TM) in the consumer market and DNAWitness(TM) in the forensic market in 2003. DNAPrint is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit: http://www.dnaprint.com.

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Media and Press Contacts Richard Gabriel DNAPrint genomics, Inc. CEO/President [phone]

SOURCE DNAPrint genomics, Inc.

Richard Gabriel, CEO and President, DNAPrint genomics, Inc.,[phone]

http://www.dnaprint.com

Copyright (C) 2004 PR Newswire. All rights reserved.